Sclerosis Clinical Trials

2 recruiting

Sclerosis Trials at a Glance

863 actively recruiting trials for sclerosis are listed on ClinicalTrialsFinder across 6 cities in 76 countries. The largest study group is Not Applicable with 273 trials, with the heaviest enrollment activity in Chicago, Boston, and New York. Lead sponsors running sclerosis studies include Novartis Pharmaceuticals, Istituto Auxologico Italiano, and Assistance Publique - Hôpitaux de Paris.

Treatments under study

About Sclerosis Clinical Trials

Looking for clinical trials for Sclerosis? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Sclerosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Sclerosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 863 trials

Recruiting

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

ObesityCardiomyopathyLi-Fraumeni Syndrome+3 more
National Heart, Lung, and Blood Institute (NHLBI)5,000 enrolled3 locationsNCT01143454
Recruiting

Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)

Multiple Sclerosis
National Institute of Neurological Disorders and Stroke (NINDS)3,750 enrolled1 locationNCT00001248
Recruiting
Phase 2

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis

Focal Segmental Glomerulosclerosis
National Human Genome Research Institute (NHGRI)30 enrolled1 locationNCT06664814
Recruiting

Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?

FatigueMultiple SclerosisHypogammaglobulinemia
Insel Gruppe AG, University Hospital Bern106 enrolled1 locationNCT05357781
Recruiting
Not Applicable

Ultra-high-caloric, Fatty Diet in ALS

Amyotrophic Lateral Sclerosis
University of Ulm392 enrolled23 locationsNCT06280079
Recruiting
Phase 1

A Study of AZD0120 in Autoimmune Diseases

Rheumatoid ArthritisIdiopathic Inflammatory MyopathiesSystemic Sclerosis
AstraZeneca27 enrolled18 locationsNCT07295847
Recruiting
Phase 2

Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

Multiple Sclerosis
National Institute of Neurological Disorders and Stroke (NINDS)30 enrolled1 locationNCT02784210
Recruiting

Study of Skin Tumors in Tuberous Sclerosis

Tuberous Sclerosis
National Heart, Lung, and Blood Institute (NHLBI)400 enrolled1 locationNCT00001975
Recruiting
Phase 1

Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy

Multiple SclerosisProgressive Multifocal Leukoencephalopathy
National Institute of Neurological Disorders and Stroke (NINDS)15 enrolled1 locationNCT05849467
Recruiting

Florbetaben for Imaging of Vascular Amyloid

StrokeAcute Coronary SyndromeTransient Ischemic Attack+1 more
Ottawa Heart Institute Research Corporation30 enrolled1 locationNCT06091319
Recruiting
Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Lupus Nephritis+2 more
Fate Therapeutics244 enrolled18 locationsNCT06308978
Recruiting

Causes and Natural History of Dyslipidemias

AtherosclerosisHypercholesterolemia
National Heart, Lung, and Blood Institute (NHLBI)2,000 enrolled1 locationNCT00353782
Recruiting
Phase 1

A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis
Insmed Gene Therapy LLC23 enrolled5 locationsNCT07290062
Recruiting
Phase 3

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis
Boehringer Ingelheim286 enrolled256 locationsNCT07220083
Recruiting
Not Applicable

Blood Flow Restriction for Upper Limb Rehabilitation in People With Multiple Sclerosis. A Randomized Controlled Trial (BFRT-EM)

Multiple Sclerosis
Universidad Rey Juan Carlos20 enrolled1 locationNCT06795230
Recruiting
Phase 3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Relapsing Multiple Sclerosis
Novartis Pharmaceuticals360 enrolled99 locationsNCT06846281
Recruiting

Smoldering Inflammation in MS

Multiple Sclerosis
Washington University School of Medicine25 enrolled1 locationNCT06591429
Recruiting
Phase 2Phase 3

HEALEY ALS Platform Trial - Master Protocol

Amyotrophic Lateral Sclerosis
Merit E. Cudkowicz, MD1,500 enrolled78 locationsNCT04297683
Recruiting
Not Applicable

Non-invasive BCI-controlled Assistive Devices

Traumatic Brain InjuryHealthyMovement Disorders+6 more
University of Texas at Austin100 enrolled1 locationNCT05183152
Recruiting
Phase 1Phase 2

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

Amyotrophic Lateral Sclerosis
Vector Y Therapeutics12 enrolled11 locationsNCT07287397